[Immunosuppressive treatment and risks of neoplasms].
The risk of neoplasma depends on the amount of mutagenic factors and the ability of immunological system to eliminate neoplasma cells. Immunosuppressive treatment administered in hematology, transplantology, nephrology, rheumatology and dermatology impairs the function of immunological system. The review of literature referring neoplasma epidemiology in the disciplines of medicine, mentioned above was made. The incidence of neoplasma in patients undergoing immunosuppressive treatment is much higher than in rest of population and depends on many factors: primary disease, type of treatment and kind of organ transplanted.
Magier
K
K
Katedry i Kliniki Nefrologii Pediatrycznej AM we Wrocławiu.
Zwolińska
D
D
D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D009369:Neoplasms / Q000209:etiology*
D007166:Immunosuppressive Agents